社论：癌症中的激素抵抗 - Suppr

Editorial: Hormone resistance in cancer.

作者信息

Phoenix John T, Budreika Audris, Kostlan Raymond J, Hwang Justin H, Fanning Sean W, Kregel Steven

机构信息

Department of Cancer Biology, Stritch School of Medicine, Loyola University Chicago, Maywood, IL, United States.

Integrated Program in Biomedical Science, Biochemistry, Molecular and Cancer Biology, Loyola University Chicago, Maywood, IL, United States.

出版信息

Front Endocrinol (Lausanne). 2023 Aug 24;14:1272932. doi: 10.3389/fendo.2023.1272932. eCollection 2023.

DOI:10.3389/fendo.2023.1272932

PMID:37693345

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10484586/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c563/10484586/f762ca2711a4/fendo-14-1272932-g001.jpg

相似文献

Editorial: Hormone resistance in cancer.

Front Endocrinol (Lausanne). 2023 Aug 24;14:1272932. doi: 10.3389/fendo.2023.1272932. eCollection 2023.

Reprogramming hormone-sensitive prostate cancer to a lethal neuroendocrine cancer lineage by mitochondrial pyruvate carrier (MPC).

Mol Metab. 2022 May;59:101466. doi: 10.1016/j.molmet.2022.101466. Epub 2022 Feb 25.

The Role of Epigenetic Change in Therapy-Induced Neuroendocrine Prostate Cancer Lineage Plasticity.

Front Endocrinol (Lausanne). 2022 Jul 14;13:926585. doi: 10.3389/fendo.2022.926585. eCollection 2022.

Lineage plasticity and treatment resistance in prostate cancer: the intersection of genetics, epigenetics, and evolution.

Front Endocrinol (Lausanne). 2023 Jun 30;14:1191311. doi: 10.3389/fendo.2023.1191311. eCollection 2023.

FOXA2 drives lineage plasticity and KIT pathway activation in neuroendocrine prostate cancer.

Cancer Cell. 2022 Nov 14;40(11):1306-1323.e8. doi: 10.1016/j.ccell.2022.10.011. Epub 2022 Nov 3.

Clinical applications of gonadotropin-releasing hormone and gonadotropin-releasing hormone analogs.

Fertil Steril. 1983 Mar;39(3):257-66.

Wntless expression promotes lineage plasticity and is associated with neuroendocrine prostate cancer.

Am J Clin Exp Urol. 2022 Oct 15;10(5):299-310. eCollection 2022.

Neuropeptides and hormones in hypothalamus-pituitary axis of Chinese sturgeon (Acipenser sinensis).

Gen Comp Endocrinol. 2023 Jan 1;330:114135. doi: 10.1016/j.ygcen.2022.114135. Epub 2022 Sep 28.

Nuclear hormone receptor variants: their role in malignancy and progression to hormone resistance in cancer.

Acta Endocrinol (Copenh). 1991;125 Suppl 1:48-53.

Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches.

J Steroid Biochem Mol Biol. 2005 Feb;93(2-5):191-200. doi: 10.1016/j.jsbmb.2004.12.002. Epub 2005 Jan 28.

引用本文的文献

Nuclear receptors in metabolic, inflammatory, and oncologic diseases: mechanisms, therapeutic advances, and future directions.

Eur J Med Res. 2025 Sep 9;30(1):843. doi: 10.1186/s40001-025-03073-6.

SOX2 utilizes FOXA1 as a heteromeric transcriptional partner to drive proliferation in therapy-resistant prostate cancer.

bioRxiv. 2025 Jul 19:2025.07.18.664790. doi: 10.1101/2025.07.18.664790.

Fractional order modeling of prostate cancer with pulsed treatment and the impact of effector cell killing and cell competition.

Sci Rep. 2025 Apr 12;15(1):12580. doi: 10.1038/s41598-025-96737-6.

The Homeobox Transcription Factor NKX3.1 Displays an Oncogenic Role in Castration-Resistant Prostate Cancer Cells.

Cancers (Basel). 2025 Jan 18;17(2):306. doi: 10.3390/cancers17020306.

本文引用的文献

Lineage plasticity enables low-ER luminal tumors to evolve and gain basal-like traits.

Breast Cancer Res. 2023 Mar 1;25(1):23. doi: 10.1186/s13058-023-01621-8.

Aggressive pituitary tumors (PitNETs).

Endocr J. 2023 Mar 28;70(3):241-248. doi: 10.1507/endocrj.EJ23-0007. Epub 2023 Mar 3.

Cancer statistics, 2023.

CA Cancer J Clin. 2023 Jan;73(1):17-48. doi: 10.3322/caac.21763.

Unconventional isoquinoline-based SERMs elicit fulvestrant-like transcriptional programs in ER+ breast cancer cells.

NPJ Breast Cancer. 2022 Dec 14;8(1):130. doi: 10.1038/s41523-022-00497-9.

ESR1 activating mutations: From structure to clinical application.

Biochim Biophys Acta Rev Cancer. 2023 Jan;1878(1):188830. doi: 10.1016/j.bbcan.2022.188830. Epub 2022 Nov 4.

ZBTB20 Regulates Prolactin Expression and Lactotrope Function in Adult Mice.

Endocrinology. 2022 Oct 23;163(12). doi: 10.1210/endocr/bqac181.

SERDs: a case study in targeted protein degradation.

Chem Soc Rev. 2022 Oct 3;51(19):8149-8159. doi: 10.1039/d2cs00117a.

DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms.

Oncologist. 2022 Nov 3;27(11):940-951. doi: 10.1093/oncolo/oyac161.

Transcriptional coactivator MED1 in the interface of anti-estrogen and anti-HER2 therapeutic resistance.

Cancer Drug Resist. 2022 Jun 1;5(2):498-510. doi: 10.20517/cdr.2022.33. eCollection 2022.

CREB5 reprograms FOXA1 nuclear interactions to promote resistance to androgen receptor-targeting therapies.

Elife. 2022 May 12;11:e73223. doi: 10.7554/eLife.73223.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Editorial: Hormone resistance in cancer.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献